Eculizumab for atypical hemolytic-uremic syndrome.
Nürnberger
Jens
J
Philipp
Thomas
T
Witzke
Oliver
O
Opazo Saez
Anabelle
A
Vester
Udo
U
Baba
Hideo Andreas
HA
Kribben
Andreas
A
Zimmerhackl
Lothar Bernd
LB
Janecke
Andreas R
AR
Nagel
Mato
M
Kirschfink
Michael
M
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003180:Complement C3b Inactivator Proteins / Q000235:genetics; D003182:Complement C5 / Q000037:antagonists & inhibitors*; D017242:Complement Factor H / Q000235:genetics*; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007668:Kidney / Q000473:pathology; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000601:surgery; D016030:Kidney Transplantation; D020125:Mutation, Missense; D012008:Recurrence; D017384:Sequence Deletion
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C517621:CFHR1 protein, human; D003180:Complement C3b Inactivator Proteins; D003182:Complement C5; D007155:Immunologic Factors; D017242:Complement Factor H; C481642:eculizumab